Silence Therapeutics plc

SLN

US82686Q1013

Market Closed - Nasdaq Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
20.48 ^USD	+0.89%		-2.43%	+17.90%

30/05	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	MT
28/05	European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	MT

Presenter SpeechSurani Fernando (Attendees)I'm thrilled to have with me Professor Kausik Ray. ...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Silence Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	30/05	MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	28/05	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	22/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	21/05	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	20/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	17/05	MT
Silence Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	16/05	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	15/05	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	13/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	09/05	MT
Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024	29/04	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	19/04	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	16/04	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	15/04	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	12/04	MT
Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	08/04	CI
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	27/03	MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading	18/03	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading	15/03	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	14/03	MT
Chardan Boosts Price Target on Silence Therapeutics to $42 From $26 on Positive Data From Zerlasiran Study, Keeps Buy Rating	14/03	MT
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating	14/03	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	13/03	MT
Silence Therapeutics Says Phase 2 Study of High Lipoprotein(a) Treatment Meets Primary Endpoint	13/03	MT

Chart Silence Therapeutics plc

Duration

Period

More charts

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is focused on discovering and developing molecules incorporating short-interfering ribonucleic acid (siRNA) to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body's natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA (mRNA), molecules that encode specific targeted disease-associated proteins in a cell. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target disease-associated genes in the liver. Its wholly owned product candidates include SLN360, for the unmet need in reducing cardiovascular risk in people born with high Lipoprotein (a) levels and SLN124, for rare hematological conditions, including thalassemia, myelodysplastic syndrome (MDS), and polycythemia vera (PV).

Sector

Calendar

12/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company